OncoMatch/Clinical Trials/NCT06074692
PARP Inhibition, Stereotactic Body Radiotherapy and Immunotherapy for Metastatic or Advanced Sarcoma (PRIMA)
Is NCT06074692 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies Camrelizumab and fluzoparib with concurrent stereotactic body radiotherapy (SBRT) for sarcoma.
Treatment: Camrelizumab and fluzoparib with concurrent stereotactic body radiotherapy (SBRT) — The aim of this study is to evaluate the efficacy and safety of PARP Inhibition and programmed cell death protein-1 (PD-1) blockade immunotherapy with concurrent stereotactic body radiotherapy (SBRT) for metastatic or advanced bone and soft tissue sarcoma.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Sarcoma
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Demographics
Prior therapy
Cannot have received: PARP inhibitor
have not received prior PARP inhibitor treatment
Cannot have received: anti-PD-1 therapy
Exception: unless no secondary resistance
Previously received the following therapies: anti-PD-1, anti-PD-L1, or anti-PD-L2 drugs or drugs targeting another stimulating or synergistic inhibition of T cell receptors (e.g., CTLA-4, OX-40, CD137) drug and secondary resistance to the drug (i.e., the best efficacy evaluation is CR, PR or SD lasting more than 4 months, but secondary tumor resistance develops after treatment).
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06074692 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior PARP inhibitor, anti-PD-1 therapy disqualifies patients from enrollment.
Is there an age limit?
Yes. Patients must be 70 years or younger and at least 10 years old.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages